Antihyperglycemic Medications and Cardiovascular Risk Reduction
نویسندگان
چکیده
منابع مشابه
Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort?
Philippe Gabriel Steg, MD Ronan Roussel, MD, PhD Glucose control is a key aspect of diabetes management. After concerns about the cardiovascular safety of several classes of antihyperglycemic agents, culminating with concerns about thiazolidinediones, the US Food and Drug Administration implemented a guidance statement in 2008 (strongly) recommending the demonstration of cardiovascular safety o...
متن کاملOptimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes
Diabetic microvascular and macrovascular complications arise from hyperglycemia, presenting an increasing healthcare burden as the diabetic population continues to grow. Clinical trial evidence indicates that antihyperglycemic medications are beneficial with regard to microvascular disease (retinopathy, renal impairment, and perhaps neuropathy); however, the benefit of aggressive use of these m...
متن کاملNew drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications.
The cardiovascular disease (CVD) risk associated with diabetes mellitus (DM) has become increasingly evident, accounting for 80% of deaths among patients with this disease1 and making CVD risk modification a key therapeutic objective in diabetic patients. Indeed, in some clinical contexts, DM has been elevated to a coronary heart disease risk equivalent for risk reduction strategies.1–4 The rap...
متن کاملHeart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.
Prevalent and incident heart failure (HF) is increased in people with type 2 diabetes mellitus, with risk directly associated with the severity of hyperglycemia. Furthermore, in patients with type 2 diabetes mellitus, mortality is increased ≈10-fold in patients with versus without HF. Reducing HF with antihyperglycemic therapies, however, has been unsuccessful until recently. In fact, HF as an ...
متن کاملOverview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease
Most individuals with type 2 diabetes mellitus have or will develop multiple independent risk factors for cardiovascular disease, particularly coronary artery disease (CAD). CAD is the leading cause of morbidity and mortality among individuals with type 2 diabetes mellitus, and treating these patients is challenging. The risk of hypoglycemia, weight gain, or fluid retention with some diabetes m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 13 شماره
صفحات -
تاریخ انتشار 2017